These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23850946)

  • 1. Phosphodiesterases: Regulators of cyclic nucleotide signals and novel molecular target for movement disorders.
    Sharma S; Kumar K; Deshmukh R; Sharma PL
    Eur J Pharmacol; 2013 Aug; 714(1-3):486-97. PubMed ID: 23850946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.
    Conti M; Beavo J
    Annu Rev Biochem; 2007; 76():481-511. PubMed ID: 17376027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity.
    Brescia M; Zaccolo M
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herbs to curb cyclic nucleotide phosphodiesterase and their potential role in Alzheimer's disease.
    Kumar A; Sharma V; Singh VP; Kaundal M; Gupta MK; Bariwal J; Deshmukh R
    Mech Ageing Dev; 2015 Jul; 149():75-87. PubMed ID: 26050556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterases in neurodegenerative disorders.
    Bollen E; Prickaerts J
    IUBMB Life; 2012 Dec; 64(12):965-70. PubMed ID: 23129425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases.
    Fischmeister R; Castro LR; Abi-Gerges A; Rochais F; Jurevicius J; Leroy J; Vandecasteele G
    Circ Res; 2006 Oct; 99(8):816-28. PubMed ID: 17038651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in targeting cyclic nucleotide phosphodiesterases.
    Maurice DH; Ke H; Ahmad F; Wang Y; Chung J; Manganiello VC
    Nat Rev Drug Discov; 2014 Apr; 13(4):290-314. PubMed ID: 24687066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.
    Lerner A; Epstein PM
    Biochem J; 2006 Jan; 393(Pt 1):21-41. PubMed ID: 16336197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.
    Keravis T; Lugnier C
    Br J Pharmacol; 2012 Mar; 165(5):1288-305. PubMed ID: 22014080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential function of phosphodiesterase families in the brain: gaining insights through the use of genetically modified animals.
    Kelly MP; Brandon NJ
    Prog Brain Res; 2009; 179():67-73. PubMed ID: 20302819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterases in the central nervous system.
    Kleppisch T
    Handb Exp Pharmacol; 2009; (191):71-92. PubMed ID: 19089326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Emerging Role of Phosphodiesterases in Movement Disorders.
    Erro R; Mencacci NE; Bhatia KP
    Mov Disord; 2021 Oct; 36(10):2225-2243. PubMed ID: 34155691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of the interaction between different phosphodiesterases and yessotoxin using a resonant mirror biosensor.
    Pazos MJ; Alfonso A; Vieytes MR; Yasumoto T; Botana LM
    Chem Res Toxicol; 2006 Jun; 19(6):794-800. PubMed ID: 16780358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases.
    Chen S; Yan C
    Expert Opin Drug Discov; 2021 Feb; 16(2):183-196. PubMed ID: 32957823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders.
    Xu Y; Zhang HT; O'Donnell JM
    Handb Exp Pharmacol; 2011; (204):447-85. PubMed ID: 21695652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.
    Cardinale A; Fusco FR
    CNS Neurosci Ther; 2018 Apr; 24(4):319-328. PubMed ID: 29500937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
    de Vente J; Markerink-van Ittersum M; Vles JS
    J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
    Manganiello V
    Mol Pharmacol; 2003 Jun; 63(6):1209-11. PubMed ID: 12761329
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting cancer with phosphodiesterase inhibitors.
    Savai R; Pullamsetti SS; Banat GA; Weissmann N; Ghofrani HA; Grimminger F; Schermuly RT
    Expert Opin Investig Drugs; 2010 Jan; 19(1):117-31. PubMed ID: 20001559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.